- Behavioural Risks Reported Globally
- Regulators Face Growing Questions
- Unexpected Behavioural Effects
Article Today, Hyderabad:
Medicines prescribed for Parkinson’s disease are facing renewed scrutiny after reports linked them to severe behavioural side effects. The drug ropinirole, a dopamine agonist, is widely used to manage tremors and movement disorders. However, patients in several countries have reported sudden changes in behaviour after starting treatment. These include compulsive gambling, hypersexuality, and impulsive spending.
How the Drug Works
Ropinirole stimulates dopamine receptors in the brain. Dopamine regulates movement and also controls reward and pleasure pathways. When dopamine activity increases artificially, it may disrupt impulse control. Therefore, some patients develop what doctors call impulse control disorders. These conditions reduce a person’s ability to assess consequences before acting.
Extent of the Risk
Medical studies suggest that up to 16 percent of patients on dopamine agonists may experience impulse-related side effects. However, the severity varies. In many cases, symptoms subside after the dose is reduced or the drug is discontinued. Meanwhile, experts stress that not every patient faces such risks. Careful monitoring remains essential.
Patient Accounts Raise Alarm
Several high-profile legal cases have brought attention to the issue. In one case in France, a patient successfully sought compensation after claiming the drug triggered compulsive gambling and risky sexual behaviour. Courts in Europe have acknowledged links between dopamine agonists and impulse control disorders in certain circumstances. However, each case depends on medical evaluation and documented evidence.
Pharmaceutical Response
GlaxoSmithKline, which previously marketed ropinirole under the brand name Requip, has updated safety warnings over the years. Patient information leaflets now mention the possibility of behavioural changes. However, critics argue that earlier warnings were insufficient. Meanwhile, generic versions of ropinirole continue to be manufactured by multiple pharmaceutical companies worldwide.
Situation in India
In India, several companies market ropinirole for Parkinson’s disease and restless legs syndrome. The drug is approved by the national regulator. Doctors say it remains an important treatment option for many patients. However, neurologists advise families to watch for unusual behavioural patterns after therapy begins. Early identification can prevent serious consequences.
Medical Community Perspective
Specialists emphasise that dopamine agonists are effective and, in many cases, necessary. Parkinson’s disease significantly affects quality of life. Therefore, treatment decisions require a balance between benefits and risks. Physicians recommend detailed counselling before starting therapy. Regular follow-up visits help detect behavioural side effects early.
Call for Vigilance
Health experts now call for stronger awareness among patients, caregivers, and clinicians. Clear communication about possible risks can reduce harm. Regulatory bodies continue to monitor safety data. As legal and medical discussions evolve, the focus remains on informed consent and patient protection while preserving access to essential treatment.
Bolloju Ravi, Senior Journalist
